Cargando…
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine (RAI) therapy, which is an effective treatment for reducing the risk of recurrence, and even the mortality, of DTC...
Autores principales: | Liu, Jierui, Liu, Yanqing, Lin, Yansong, Liang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769341/ https://www.ncbi.nlm.nih.gov/pubmed/31565873 http://dx.doi.org/10.3803/EnM.2019.34.3.215 |
Ejemplares similares
-
SAT520 Efficacy of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers
por: Toro-Tobon, David, et al.
Publicado: (2023) -
Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib
por: Zayouna, Christine, et al.
Publicado: (2021) -
Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers
por: Oh, Ji Min, et al.
Publicado: (2022) -
Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer
por: Mu, Zhuan-Zhuan, et al.
Publicado: (2019) -
Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis
por: Wang, Chen, et al.
Publicado: (2017)